Plasminogen Activity

Clinical Use

Order Test

Use

Monitor thrombolytic therapy; evaluate ligneous tissue depositions such as conjunctivitis

Special Instructions

Not provided.

Limitations

Plasminogen levels can be decreased in various conditions such as disseminated intravascular coagulation (DIC), hepatitis, leukemia, and with thrombolytic therapy. Furthermore, hereditary deficiencies in plasminogen activity, including types I and II, affect the test results. Care should be taken with interpretation in individuals undergoing anticoagulant therapy as it may impact plasminogen levels.

Test Details

Methodology

Other

Biomarkers

LOINC Codes

Order Codes

28660-9 - PLG Act/Nor PPP Chro

Result Codes

28660-9 - PLG Act/Nor PPP Chro

Result Turnaround Time

2-3 days

Specimen

Plasma

Volume

1 mL

Minimum Volume

Not provided

Container

Blue-top (sodium citrate) tube

Collection Instructions

Citrated plasma samples should be collected by double centrifugation. Blood should be collected in a blue-top tube containing 3.2% buffered sodium citrate. The sample should be mixed immediately by gentle inversion at least six times to ensure adequate mixing of the anticoagulant with the blood. Deliver to a plastic transport tube, cap, and recentrifuge for 10 minutes. Use a second plastic pipette to remove the plasma. Transfer the plasma into a Labcorp PP transpak frozen purple tube with screw cap (Labcorp No. 49482). Freeze immediately and maintain frozen until tested.

Patient Preparation

Ideally, the patient should not be on anticoagulant therapy. Avoid warfarin (Coumadin®) therapy for two weeks prior to the test and heparin, direct Xa, and thrombin inhibitor therapies for about three days prior to testing.

Storage Instructions

Freeze.

Causes for Rejection

Severe hemolysis; improper labeling; clotted specimen; specimen diluted with IV fluids; samples thawed in transit; improper sample type; sample out of stability